Efficacy and safety of bemiparin as treatment of venous thromboembolic disease in the elderly
Journal of Evaluation in Clinical Practice · 2024
DOI: 10.1111/jep.14025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Evaluation in Clinical Practice, 2024. Verfasst von Javier Ena und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Hospital Marina Baixa, Alicante, Spain. Hauptthemen laut MEDLINE: Venous Thromboembolism, Heparin, Low-Molecular-Weight, Hemorrhage. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
As the elderly population continues to grow worldwide, it becomes crucial to explore safe and effective treatment options to manage venous thromboembolic disease in this vulnerable demographic group.
Methods
We carried out a retrospective cohort study (January 2017–December 2021) to analyse the efficacy and safety of bemiparin as a treatment for venous thromboembolic disease in 223 patients. We compared patients aged ≥65 years (elderly; n = 153) with patients aged less than 65 years (adults; n = 70) for a combined end point of death, recurrent thromboembolism, and major bleeding at 30 days.
Results
Elderly (mean age 79 ± 7.7 years) and adult patients (mean age 51.5 ± 11.6 years) received similar bemiparin doses 8470 ± 2362 International units (IU)/d versus 8754 ± 1593 IU/d, during a similar median [Interquartile range] period of 28 [9–118] versus 30 [10–90] days, respectively. At 30‐day follow up a total of 24 elderly patients (15.7%), reached at least one of the end points, as compared with six adult patients (8.6%) (absolute difference 7.1%; 95% confidence interval [95% CI], −1.6 to 15.8). Recurrence of venous thromboembolic disease occurred in five elderly patients (3.3%) and in five adult patients (7.1%) (absolute difference −3.9%; 95% CI, −10.5 to 2.8). There were two episodes of major bleeding each in elderly (1.3%) and adult (2.9%) patients (absolute difference −1.6%; 95% CI, −5.8 to 2.7).
Conclusion
Bemiparin showed a similar efficacy and safety profile in the treatment of venous thromboembolic disease in elderly and adult patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Hospital Marina Baixa, Alicante, Spain.
ORCID-Profile: Javier Ena
Zitieren
APA
Ena, J., Stanimirova-Nikolova, S., Iborra-Devesa, M., Raya-Santos, C., Serra-Manclus, A., & Seco-Hanselaar, I. J. (2024). Efficacy and safety of bemiparin as treatment of venous thromboembolic disease in the elderly. Journal of Evaluation in Clinical Practice. https://doi.org/10.1111/jep.14025
Vancouver
Ena J, Stanimirova-Nikolova S, Iborra-Devesa M, Raya-Santos C, Serra-Manclus A, Seco-Hanselaar IJ. Efficacy and safety of bemiparin as treatment of venous thromboembolic disease in the elderly. Journal of Evaluation in Clinical Practice. 2024. doi:10.1111/jep.14025
BibTeX
@article{Ena2024,
author = {Ena, Javier and Stanimirova-Nikolova, Silvena and Iborra-Devesa, Maria and Raya-Santos, Carmen and Serra-Manclus, Aurora and Seco-Hanselaar, Ignacio J},
title = {Efficacy and safety of bemiparin as treatment of venous thromboembolic disease in the elderly},
journal = {Journal of Evaluation in Clinical Practice},
year = {2024},
doi = {10.1111/jep.14025}
}
EUVIMED